151 related articles for article (PubMed ID: 28490612)
1. Pathology update to the Manchester Scoring System based on testing in over 4000 families.
Evans DG; Harkness EF; Plaskocinska I; Wallace AJ; Clancy T; Woodward ER; Howell TA; Tischkowitz M; Lalloo F
J Med Genet; 2017 Oct; 54(10):674-681. PubMed ID: 28490612
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.
Kast K; Schmutzler RK; Rhiem K; Kiechle M; Fischer C; Niederacher D; Arnold N; Grimm T; Speiser D; Schlegelberger B; Varga D; Horvath J; Beer M; Briest S; Meindl A; Engel C
Int J Cancer; 2014 Nov; 135(10):2352-61. PubMed ID: 24700448
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting
Chew W; Moorakonda RB; Courtney E; Soh H; Li ST; Chen Y; Shaw T; Allen JC; Evans DGR; Ngeow J
J Med Genet; 2018 May; 55(5):344-350. PubMed ID: 29275357
[TBL] [Abstract][Full Text] [Related]
4. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
[TBL] [Abstract][Full Text] [Related]
5. Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
Evans DG; Woodward ER; Howell SJ; Verhoef S; Howell A; Lalloo F
Fam Cancer; 2017 Apr; 16(2):173-179. PubMed ID: 27796713
[TBL] [Abstract][Full Text] [Related]
6. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing.
Evans DG; Lalloo F; Cramer A; Jones EA; Knox F; Amir E; Howell A
J Med Genet; 2009 Dec; 46(12):811-7. PubMed ID: 19542080
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Thirthagiri E; Lee SY; Kang P; Lee DS; Toh GT; Selamat S; Yoon SY; Taib NA; Thong MK; Yip CH; Teo SH
Breast Cancer Res; 2008; 10(4):R59. PubMed ID: 18627636
[TBL] [Abstract][Full Text] [Related]
8. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of probability of BRCA1 and BRCA2 mutations carriage in women with compromised family history of breast and/or ovarian cancer.
Rybchenko LA; Bychkova AM; Skyban GV; Klymenko SV
Probl Radiac Med Radiobiol; 2013; (18):253-60. PubMed ID: 25191729
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.
Simard J; Dumont M; Moisan AM; Gaborieau V; Malouin H; Durocher F; Chiquette J; Plante M; Avard D; Bessette P; Brousseau C; Dorval M; Godard B; Houde L; ; Joly Y; Lajoie MA; Leblanc G; Lépine J; Lespérance B; Vézina H; Parboosingh J; Pichette R; Provencher L; Rhéaume J; Sinnett D; Samson C; Simard JC; Tranchant M; Voyer P; Easton D; Tavtigian SV; Knoppers BM; Laframboise R; Bridge P; Goldgar D
J Med Genet; 2007 Feb; 44(2):107-21. PubMed ID: 16905680
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
12. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
13. [A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition].
Bonaïti B; Alarcon F; Bonadona V; Pennec S; Andrieu N; Stoppa-Lyonnet D; Perdry H; Bonaïti-Pellié C;
Bull Cancer; 2011 Jul; 98(7):779-95. PubMed ID: 21708517
[TBL] [Abstract][Full Text] [Related]
14. A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.
Bonaïti B; Alarcon F; Andrieu N; Bonadona V; Dondon MG; Pennec S; Stoppa-Lyonnet D; Bonaïti-Pellié C; Perdry H
J Med Genet; 2014 Feb; 51(2):114-21. PubMed ID: 24343917
[TBL] [Abstract][Full Text] [Related]
15. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
16. Clinical management of women with genomic BRCA1 and BRCA2 mutations.
Chang J; Elledge RM
Breast Cancer Res Treat; 2001 Sep; 69(2):101-13. PubMed ID: 11759816
[TBL] [Abstract][Full Text] [Related]
17. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing.
Evans DG; Lalloo F; Wallace A; Rahman N
J Med Genet; 2005 Jul; 42(7):e39. PubMed ID: 15994864
[No Abstract] [Full Text] [Related]
18. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
Evans DG; Eccles DM; Rahman N; Young K; Bulman M; Amir E; Shenton A; Howell A; Lalloo F
J Med Genet; 2004 Jun; 41(6):474-80. PubMed ID: 15173236
[TBL] [Abstract][Full Text] [Related]
19. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
James PA; Doherty R; Harris M; Mukesh BN; Milner A; Young MA; Scott C
J Clin Oncol; 2006 Feb; 24(4):707-15. PubMed ID: 16446345
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
